成人免疫性血小板减少症初始治疗应单用地塞米松还是联合用药:仍是一个相关问题
本文讨论成人新诊断免疫性血小板减少症(ITP)一线糖皮质激素选择:泼尼松(PDN)与地塞米松的争议。地塞米松四天周期升血小板更快、严重不良事件似更少,但治愈优势未充分证实;地塞米松联合利妥昔单抗较单用地塞米松缓解率更高、长期结果更好。
要点
- 地塞米松四天周期较泼尼松升血小板更快,严重不良事件似更少。
- 地塞米松相对于泼尼松的治愈优势未被充分证实。
- 地塞米松联合利妥昔单抗一线治疗缓解率更高、长期结果更好。
核心结论
- 地塞米松四天周期升血小板更快且严重不良事件似更少,但相对于泼尼松的治愈优势未被充分证实。
- 地塞米松联合利妥昔单抗一线治疗较高剂量地塞米松单药缓解率更高、长期结果更好,对年轻女性尤佳。
研究设计与样本
- 本文为综述,讨论成人新诊断ITP一线糖皮质激素选择的相关研究。
主要发现
- 地塞米松四天周期较泼尼松升血小板更快,且似减少严重不良事件发生。
- 地塞米松治疗总体似更安全,所有不良事件发生率低于泼尼松,可能反映疗程更短及累积激素剂量更低。
- 地塞米松联合利妥昔单抗一线治疗较高剂量地塞米松单药缓解率更高、长期结果更好。
临床怎么用
- 对血小板计数低且伴出血素质的患者,地塞米松可能是更好的选择。
- 地塞米松联合利妥昔单抗对年轻女性是尤其好的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Corticosteroids are used in first-line treatment in newly diagnosed immune thrombocytopenia. The goal of treatment is primarily to decrease autoantibody-mediated platelet clearance. Ideally initial treatment would not just increase the platelet count but also provide a long-term sustained remission. While many clinicians use prednisone (PDN) as their first choice of corticosteroid, others prefer dexamethasone. The controversy is the subject of debates. Short courses of higher-dose corticosteroids were first reported by the Andersen study in 1994. The study posited high-dose dexamethasone as a 'cure' for all ITP patients. Later, studies addressed the number of dexamethasone cycles, indications to repeat cycles and timing between cycles, with varied long-term results. The results with dexamethasone were compared to PDN in some studies: the four-day cycles of dexamethasone work faster in increasing platelet counts and appear to reduce the occurrence of severe adverse events. Therefore, it is probably a better option for patients with low platelet counts and bleeding diathesis; however, curative superiority, the initial reason to administer it, compared to PDN is not well demonstrated. Across the studies, treatment with high-dose dexamethasone seems to be safer, with lower incidence of all adverse events compared to PDN, which might be a reflection of shorter treatment duration and possibly also lower cumulative steroid dose. Dexamethasone in combination with rituximab in first-line treatment produced higher response rates with better long-term results compared to high-dose dexamethasone alone and is a particularly good option in younger women.
引用
- Skopec B, Bussel JB. Should dexamethasone alone or in combination be the initial steroid for adult ITP: Still a relevant question. Br J Haematol. 2022. PMID: 35922885. doi:10.1111/bjh.18398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。